Tim Demuth News Today

EQS-News: MorphoSys AG / Key word: Conference MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference  08.01.2024 / 08:00 CET/CEST The issuer is...

EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in...

The drug researcher Morphosys has achieved a breakthrough in clinical trials with its promising drug pelabresib against the rare blood cancer myelofibrosis. In a pivotal study, the Bavarians hit their...

MorphoSys AG (NASDAQ:MOR) Q3 2023 Earnings Call Transcript November 16, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Third Quarter Statement 2023 of MorphoSys. Throughout today’s recorded call, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. [Operator […]

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting 02.11.2023 / 14:05 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, Novemb...

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis ...

The FDA has granted fast track designation to tulmimetostat for use as a potential therapeutic option in patients with advanced, recurrent, or metastatic endometrial cancer harboring ARID1A mutations and whose disease had progressed on at least 1 prior line of therapy.

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer 12.09.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, September 12, 2023 MorphoSys Receiv...

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat ...

EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Receives U.S. FDA Fast Track Designation for Tulmime...